REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
This article is part of the Research TopicThe Role of Immunotherapy in Cancer Therapy and Its ChallengesView all 27 articles
Novel Immunotherapeutic Strategies For Diffuse Large B-Cell Lymphoma: A Comprehensive Review
Provisionally accepted
- 1Zhejiang Chinese Medical University, Hangzhou, China
- 2Hangzhou Normal University, Hangzhou, China
- 3Hangzhou First People's Hospital, Hangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Diffuse large B-cell lymphoma (DLBCL) represents the most prevalent histological subtype of non-Hodgkin lymphoma, characterized by pronounced clinical and biological heterogeneity. Despite the incorporation of rituximab into the cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen—achieving durable remission in approximately 60% of patients—30%–40% ultimately experience relapse or develop refractory disease, resulting in unfavorable clinical outcomes. Over the past decade, the advent of novel immunotherapeutic approaches has reshaped the therapeutic paradigm for relapsed/refractory (R/R) DLBCL. Emerging modalities, including monoclonal antibodies, immune checkpoint inhibitors, chimeric antigen receptor T-cell (CAR-T) therapies, antibody–drug conjugates, and bispecific antibodies, have demonstrated encouraging efficacy across multiple clinical settings. Nevertheless, the intrinsic complexity of resistance mechanisms, coupled with the substantial cost and limited accessibility of advanced molecular diagnostics, continues to hinder optimal disease management. This review summarizes the commonly used therapeutic strategies for DLBCL, discusses recent advances, and aims to provide insights for the future development of personalized treatment approaches.
Keywords: ADCS, bispecific antibodies, CAR-T cell therapy, Diffuse large B-cell lymphoma, immune checkpoint inhibitors, Immunotherapy
Received: 12 Sep 2025; Accepted: 16 Feb 2026.
Copyright: © 2026 李, Zhang, Zhu, Han, Gao, Wang and Yue. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Ying Wang
Juanqing Yue
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.